Expression of AS3MT alters transcriptional profiles in human urothelial cells exposed to arsenite

Human and Experimental Toxicology

Volumn 28, Issue 1, 2009, Pages 49-61

  Hester, S D ^a   Drobna Z ^b   Andrews, D M K ^c   Liu, J ^d   Waalkes, M P ^d   Thomas, D J ^a   Styblo M ^b,e  

^a U S ENVIRONMENTAL PROTECTION AGENCY   (United States)

^b IL   (United States)

^c NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

^e UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Arsenite; AS3MT; Human urothelial cells; Transcriptional profiles

Indexed keywords

ARSENIC DERIVATIVE; ARSENIC METHYLTRANSFERASE; ARSENIC TRIOXIDE; GUANINE NUCLEOTIDE BINDING PROTEIN; PHOSPHOTRANSFERASE; UNCLASSIFIED DRUG;

ARTICLE; CATALYSIS; CELL ADHESION; CELL CYCLE REGULATION; CELL DEATH; CELL DIFFERENTIATION; CELL GROWTH; CELL LINE; CONCENTRATION RESPONSE; CYTOTOXICITY; ENVIRONMENTAL EXPOSURE; GENE; GENE EXPRESSION PROFILING; GENETIC ANALYSIS; GENOMICS; HUMAN; HUMAN CELL; METHYLATION; MUTATION; NUCLEOTIDE METABOLISM; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; TRANSCRIPTION REGULATION; UROTHELIUM;

ANIMALS; ARSENITES; CARCINOGENS, ENVIRONMENTAL; CELL LINE, TRANSFORMED; CLONE CELLS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; METHYLATION; METHYLTRANSFERASES; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PRINCIPAL COMPONENT ANALYSIS; RATS; UROTHELIUM;

RATTUS;

EID: 65449168428     PISSN: 09603271     EISSN: None     Source Type: Journal    
DOI: 10.1177/0960327109102368     Document Type: Article

References (27)

1. Thomas DJ., Li J., Waters SB., Xing W., Adair BM., Drobna Z., Devesa V.,. Arsenic (+3 oxidation state) methyltransferase and the methylation of arsenicals. Exp Biol Med (Maywood) 2007 ; 232: 3 - 13.
2. Thomas DJ., Waters SB., Styblo M.,. Elucidating the pathway for arsenic methylation. Toxicol Appl Pharmacol 2004 ; 198: 319 - 326. (Pubitemid 38969961)
3. Li J., Waters SB., Drobna Z., Devesa V., Styblo M., Thomas DJ.,. Arsenic (+3 oxidation state) methyltransferase and the inorganic arsenic methylation phenotype. Toxicol Appl Pharmacol 2005 ; 204: 164 - 169.
4. Lin S., Shi Q., Nix FB., Styblo M., Beck MA., Herbin-Davis KM.,. A novel S-adenosyl-L-methionine:arsenic(III) methyltransferase from rat liver cytosol. J Biol Chem 2002 ; 277: 10795 - 10803.
5. Devesa V., Del Razo LM., Adair B., Drobná Z., Waters SB., Hughes MF.,. Comprehensive analysis of arsenic metabolites by pH-specific hydride generation atomic absorption spectrometry. J Anal At Spectrom 2004 ; 19: 1460 - 1467.
6. Hernandez-Zavala A., MatouÅáek T., Drobná Z., Adair BM., Ddina J., Thomas DJ.,. Speciation of arsenic in biological matrices by automated hydride gneration-cryotrapping-atomic absorption spectrometry with multiple microflame quartz tube atomizer (multiatomizer). J Anal At Spectom 2008 ; 23.
7. Thomas DJ., Styblo M., Lin S.,. The cellular metabolism and systemic toxicity of arsenic. Toxicol Appl Pharmacol 2001 ; 176: 127 - 144.
8. Styblo M., Drobná Z., Jaspers I., Lin S., Thomas DJ.,. The role of biomethylation in toxicity and carcinogenicity of arsenic: a research update. Environ Health Perspect 2002 ; 110 (Suppl. 5): 767 - 771.
9. Petrick JS., Jagadish B., Mash EA., Aposhian HV.,. Monomethylarsonous acid (MMA(III)) and arsenite: LD(50) in hamsters and in vitro inhibition of pyruvate dehydrogenase. Chem Res Toxicol 2001 ; 14: 651 - 656. (Pubitemid 32565713)
10. Drobná Z., Waters SB., Walton FS., LeCluyse EL., Thomas DJ., Styblo M.,. Interindividual variation in the metabolism of arsenic in cultured primary human hepatocytes. Toxicol Appl Pharmacol 2004 ; 201: 166 - 177.
11. Drobná Z., Waters SB., Devesa V., Harmon AW., Thomas DJ., St?1/2blo M.,. Metabolism and toxicity of arsenic in human urothelial cells expressing rat arsenic (+3 oxidation state)-methyltransferase. Toxicol Appl Pharmacol 2005 ; 207: 147 - 159. (Pubitemid 41133501)
12. Styblo M., Yamauchi H., Thomas DJ.,. Comparative in vitro methylation of trivalent and pentavalent arsenicals. Toxicol Appl Pharmacol 1995 ; 135: 172 - 178. (Pubitemid 26031867)
13. Dai H., Meyer M., Stepaniants S., Ziman M., Stoughton R.,. Use of hybridization kinetics for differentiating specific from non-specific binding to oligonucleotide microarrays. Nucleic Acids Res 2002 ; 30: e86.
14. Schadt EE., Li C., Ellis B., Wong WH.,. Feature extraction and normalization algorithms for high-density oligonucleotide gene expression array data. J Cell Biochem Suppl 2001 ; (Suppl 37): 120 - 125.
15. Styblo M., Del Razo LM., Vega L., Germolec DR., LeCluyse EL., Hamilton GA.,. Comparative toxicity of trivalent and pentavalent inorganic and methylated arsenicals in rat and human cells. Arch Toxicol 2000 ; 74: 289 - 299. (Pubitemid 30660931)
16. Petrick JS., Ayala-Fierro F., Cullen WR., Carter DE.,. Monomethylarsonous acid (MMA(III)) is more toxic than arsenite in Chang human hepatocytes. Toxicol Appl Pharmacol 2000 ; 163: 203 - 207. (Pubitemid 30152096)
17. Drobna Z., Jaspers I., Thomas DJ., Styblo M.,. Differential activation of AP-1 in human bladder epithelial cells by inorganic and methylated arsenicals. FASEB J 2003 ; 17: 67 - 69.
18. Paul DS.,. Molecular mechanisms of the diabetogenic effects of arsenic: inhibition of insulin signaling by arsenite and methylarsonous acid. Environ Health Perspect 2007 ; 115: 734 - 742. (Pubitemid 46785043)
19. Vega L., Styblo M., Patterson R., Cullen W., Wang C., Germolec D.,. Differential effects of trivalent and pentavalent arsenicals on cell proliferation and cytokine secretion in normal human epidermal keratinocytes. Toxicol Appl Pharmacol 2001 ; 172: 225 - 232. (Pubitemid 32406030)
20. Benbrahim-Tallaa L., Waterland RA., Styblo M., Achanzar WE., Webber MM., Waalkes MP.,. Molecular events associated with arsenic-induced malignant transformation of human prostatic epithelial cells: aberrant genomic DNA methylation and K-ras oncogene activation. Toxicol Appl Pharmacol 2005 ; 206: 288 - 298. (Pubitemid 41020671)
21. Bredfeldt TG., Jagadish B., Eblin KE., Mash EA., Gandolfi AJ.,. Monomethylarsonous acid induces transformation of human bladder cells. Toxicol Appl Pharmacol 2006 ; 216: 69 - 79.
22. Sens DA., Park S., Gurel V., Sens MA., Garrett SH., Somji S.,. Inorganic cadmium- and arsenite-induced malignant transformation of human bladder urothelial cells. Toxicol Sci 2004 ; 79: 56 - 63.
23. Su PF., Hu YJ., Ho IC., Cheng YM., Lee TC.,. Distinct gene expression profiles in immortalized human urothelial cells exposed to inorganic arsenite and its methylated trivalent metabolites. Environ Health Perspect 2006 ; 114: 394 - 403. (Pubitemid 43338265)
24. Zhou XD., Sens DA., Sens MA., Namburi VB., Singh RK., Garrett SH.,. Metallothionein-1 and -2 expression in cadmium- or arsenic-derived human malignant urothelial cells and tumor heterotransplants and as a prognostic indicator in human bladder cancer. Toxicol Sci 2006 ; 91: 467 - 475.
25. Zhou P., Kalakonda N., Comenzo RL.,. Changes in gene expression profiles of multiple myeloma cells induced by arsenic trioxide (ATO): possible mechanisms to explain ATO resistance in vivo. Br J Haematol 2005 ; 128: 636 - 644. (Pubitemid 40343233)
26. Peng Z., Peng L., Fan Y., Zandi E., Shertzer HG., Xia Y.,. A critical role for IkappaB kinase beta in metallothionein-1 expression and protection against arsenic toxicity. J Biol Chem 2007 ; 282: 21487 - 21496. (Pubitemid 47099968)
27. Styblo M., Del Razo LM., LeCluyse EL., Hamilton GA., Wang C., Cullen WR.,. Metabolism of arsenic in primary cultures of human and rat hepatocytes. Chem Res Toxicol 1999 ; 12: 560 - 565.